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Abstract: The antidiabetic drug gliclazide is partly metabolized by CYP2C19, the main enzyme
involved in omeprazole metabolism. The aim of the study was to explore the interaction between
omeprazole and gliclazide in relation to CYP2C19 phenotype using physiologically based phar-
macokinetic (PBPK) modeling approach. Developed PBPK models were verified using in vivo
pharmacokinetic profiles obtained from a clinical trial on omeprazole-gliclazide interaction in healthy
volunteers, CYP2C19 normal/rapid/ultrarapid metabolizers (NM/RM/UM). In addition, the associ-
ation of omeprazole cotreatment with gliclazide-induced hypoglycemia was explored in 267 patients
with type 2 diabetes (T2D) from the GoDARTS cohort, Scotland. The PBPK simulations predicted
1.4–1.6-fold higher gliclazide area under the curve (AUC) after 5-day treatment with 20 mg omepra-
zole in all CYP2C19 phenotype groups except in poor metabolizers. The predicted gliclazide AUC
increased 2.1 and 2.5-fold in intermediate metabolizers, and 2.6- and 3.8-fold in NM/RM/UM group,
after simulated 20-day dosing with 40 mg omeprazole once and twice daily, respectively. The pre-
dicted results were corroborated by findings in patients with T2D which demonstrated 3.3-fold
higher odds of severe gliclazide-induced hypoglycemia in NM/RM/UM patients concomitantly
treated with omeprazole. Our results indicate that omeprazole may increase exposure to gliclazide
and thus increase the risk of gliclazide-associated hypoglycemia in the majority of patients.
Keywords: omeprazole; gliclazide; CYP2C19; physiologically based pharmacokinetic modeling; drug–
drug interaction; drug–drug–gene interaction; type 2 diabetes; adverse drug reaction; hypoglycemia
1. Introduction
After metformin, sulfonylureas (SUs) are the most commonly prescribed drugs
in the treatment of type 2 diabetes (T2D) worldwide [1]. This is due to their high ef-
ficacy and least cost, despite the development of newer antidiabetic agents. SUs are
particularly widely used in low and middle-income countries, where they are recom-
mended as the treatment of choice for T2D when metformin monotherapy fails to achieve
glycemic targets [2].
Hypoglycemia is the most common and potentially most serious side effect of sul-
fonylurea treatment [3]. Severe hypoglycemia is associated with significantly increased
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morbidity and mortality [4–6]. Among different SUs, gliclazide is recommended as the
treatment of choice in many countries, as it seems to be associated with a lower risk of
hypoglycemia and lower morbidity and mortality compared with other SUs [7,8]. Further-
more, gliclazide has been included in the WHO Model List of Essential Medicines, based
on its safety data in elderly patients. However, in a large-population-based cohort study,
gliclazide showed a similar risk of hypoglycemia compared with other SUs [9].
Gliclazide is extensively metabolized in the liver to inactive metabolites. Although
CYP2C9 enzyme is involved in its metabolism [10], gliclazide pharmacokinetics (PK) seem
to be affected by CYP2C19 genetic polymorphisms [11,12]. Observed gliclazide AUC was
3.4-fold [11] and 5.1-fold [12] higher in CYP2C19 poor metabolizers (PM) compared to
normal metabolizers (NM) following single oral administration of gliclazide in healthy
Chinese volunteers.
Gastrointestinal (GI) problems, such as gastroesophageal reflux disease, are common
in patients with T2D [13]. The prevalence of GI symptoms in those patients could be as high
as 40% [13]. Considering that about 70% of patients with diabetes use oral hypoglycemic
agents, millions of individuals are exposed to concomitant use of oral antidiabetic and
acid-suppressing medications [14]. Proton pump inhibitors (PPIs) are the treatment of
choice for gastroesophageal reflux disease and are primarily metabolized by CYP2C19 [15].
The potential for drug-drug interactions (DDI) is highest for omeprazole and its stereo-
isomer esomeprazole, both metabolized almost entirely by CYP2C19 [15,16]. Furthermore,
the impact of PPIs on the PK, pharmacodynamics, and therapeutic response of drugs
metabolized by CYP2C19 was shown to depend on CYP2C19 genotype, with the highest
effect seen in CYP2C19 NM [17,18] and ultrarapid metabolizers (UM) [19].
Physiologically based pharmacokinetic (PBPK) modeling is well established in the
pharmaceutical industry and is accepted by regulatory agencies for the prediction of DDIs
of new drugs [20–22]. It has been widely used especially for CYP-mediated DDIs [23].
Considering the possibility of interaction via CYP2C19, we aimed to explore the im-
pact of omeprazole on gliclazide PK, in relation to CYP2C19 phenotype using a PBPK
approach. Developed PBPK models were validated using in vivo PK profiles obtained
in a clinical trial on omeprazole-gliclazide interaction in healthy volunteers, CYP2C19
normal/rapid/ultrarapid metabolizers (NM/RM/UM). Finally, the possible interaction be-
tween the two drugs was explored in the cohort of patients with T2D treated
with gliclazide.
2. Materials and Methods
2.1. PBPK Modeling and Simulations
The PBPK models were constructed using Simcyp Simulator (version 19.1, Certara
UK Ltd., Sheffield, UK). Clinical data from the literature were used to verify the models
for each drug. Graphical data of the published mean plasma concentration-time profiles
were digitized using GetData Graph Digitizer (version 2.26, S. Fedorov). Simcyp default
values for ‘Sim-Healthy Volunteers’ were used for healthy Caucasian population, except
for phenotype frequencies of CYP2C9 and CYP2C19 enzymes, and their abundances in
the liver. Considering that both enzymes are highly polymorphic, the latest published
frequencies for the European population were used. For CYP2C9, the following frequencies
were entered: 0.629 for NM (extensive metabolizer, EM), 0.345 for intermediate metaboliser
(IM), and 0.026 for PM phenotype [24]. For CYP2C19, phenotype frequencies for the
European population were: 0.319 for RM/UM (0.047 for UM and 0.272 for RM), 0.396 for
NM (EM), 0.261 for IM and 0.025 for PM phenotype [25]. In Simcyp, differences in CYP
activities between phenotypes are accounted for using functional enzyme abundances
(pmol of enzyme/mg of microsomal protein). For CYP2C9, we used Simcyp default liver
abundance values for EM individuals, whereas abundances for other phenotypes were
adjusted based on the estimated enzyme activities compared to the EM phenotype. Thus,
liver abundance for CYP2C9 EM was set to 73, for IM to 47.6 and for PM phenotype to
13.7 pmol/mg protein (corresponding to activity scores of 2.0, 1.0–1.5, and 0–0.5 for NM,
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IM and PM phenotype, respectively) [24]. For CYP2C19, we used Simcyp default liver
abundance values for EM and UM phenotypes, 4.4 and 8.7 pmol/mg protein, respectively,
and a mean value of 6.6 pmol/mg for the RM phenotype. For IM phenotype abundance
was set to 1.32, and for PM to 0.022 pmol/mg (corresponding to activity scores of 0.30 and
0.005 for IM and PM compared to EM phenotype, respectively) [26].
2.1.1. Omeprazole Model Construction and Validation
The minimal PBPK model for omeprazole was developed based on previously pub-
lished models [27,28]. The input parameters are given in Table 1. Absorption was described
by a first-order absorption model in line with previous studies [27,28]. The steady-state
volume of distribution (Vss) value was based on previous models [28,29]. The intrinsic
clearance values per pmol of enzymes were back calculated from the clinical data after oral
administration of a single dose of omeprazole in subjects with a functional CYP2C19 [30],
taking into account the estimated contributions of CYPs to the metabolism of omeprazole
(fm) in CYP2C19 NM/RM/UM metabolizers [31]. As omeprazole is also a mechanism-
based inhibitor of CYP2C19, the values for the inhibitor concentration that supports half
the maximal rate of inactivation (Kapp) and maximal rate of enzyme inactivation (kinact),
were optimized to fit the observed concentration-time profiles after single and multiple
oral dosing of 20 mg and 40 mg omeprazole.
For model validation, clinical PK data from the literature following single and multiple
oral administration of 20 mg and 40 mg omeprazole were used [30]. The simulations were
performed using 10 virtual trials with 10 individuals in each trial, matched for age, gender,
body weight and CYP2C19 phenotype with clinical trial subjects [30].
2.1.2. Gliclazide Model Construction and Validation
The full PBPK model was developed for gliclazide using a middle-out approach.
The input parameter values are shown in Table 2. The Vss was predicted by Simcyp
Rodgers et al. + ion membrane permeability model. The Kp scalar of 3.5 was used to adjust
the predicted Vss value to those observed in humans in vivo (0.19–0.46 L/kg) [32–35].
The intrinsic clearances per pmol of CYP enzymes were calculated using total intrinsic
clearance measured in vitro in human liver microsomes [10], and fm values obtained from
in vivo data [36]. The drug clearance based only on enzyme kinetics data was underpre-
dicted around 3-fold in comparison to the in vivo i.v. data [35], indicating that active drug
uptake into the liver should also be considered. As a recent study showed that gliclazide is
a substrate of hepatic OATP1B1 transporter [37], a permeability limited liver model was
used and in vitro values for Michaelis–Menten constant (Km) and maximum transport rate
(Jmax) obtained in human embryonic kidney (HEK293T) cells stably expressing OATP1B1,
were added as inputs to simulate active drug uptake into the liver. Considering the differ-
ence in abundance and activity of the transporter between liver and the transfected cell
line, a relative activity factor (RAF) was optimized to fit the observed clinical data. Liver
passive diffusion clearance (ClPD) of gliclazide was estimated [38] based on experimental
logD7.4 value [39].
The Simcyp Advanced Dissolution, Absorption and Metabolism (ADAM) model was
used to simulate gliclazide absorption from the GI tract. For oral immediate-release (IR)
formulations, the Simcyp Diffusion Layer Model was used to predict drug dissolution
based on the published experimentally obtained pH-dependent solubility data [40]. For
modified-release (MR) formulations, our experimental dissolution profiles were used. Since
the previous study suggested that gliclazide is a substrate for the efflux Mrp2 transporter
in rats [41], simulation of the effect of intestinal MRP2 was included in the model. Value for
MRP2-mediated intrinsic clearance (Clint,T) was optimized to fit the predicted PK profiles
with the observed clinical data after oral drug dosing.
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Table 1. Input parameters for omeprazole physiologically based pharmacokinetic (PBPK) model.
Parameter Value Method/Reference
Physicochemical properties
Molecular weight (g/mol) 345.4
Log P 2.23 Ogilvie et al., 2011 [27]
pKa 4.4; 8.7 Ogilvie et al., 2011 [27]
Compound type Ampholyte Ogilvie et al., 2011 [27]
B/P 0.59 Ogilvie et al., 2011 [27]
fu 0.043 Ogilvie et al., 2011 [27]
Absorption
Absorption model First-order
fa 1 Ogilvie et al., 2011 [27]
ka (1/h) 6 Ogilvie et al., 2011 [27]
Qgut (L/h) 18.6 Predicted by Simcyp
fugut 0.043 Equal to fu (assumed)
Distribution
Distribution model Minimal PBPK model
Vss (L/kg) 0.15 Deng 2016 [29], Wu et al., 2014 [28]
Elimination
ClR (L/h) 0.037
Wu et al., 2014 [28], Feng et al., 2015
[42]
fm CYP2C19 (%) 86 Literature data (a)
fm CYP3A4 (%) 14 Literature data (a)
Clint CYP2C19
(µL/min/pmol) 75.1 Calculated (b)
Clint CYP3A4 (µL/min/pmol) 0.39 Calculated (b)
Interaction
Ki CYP2C19 (µM) 5 Ogilvie et al., 2011 [27]
fumic 1 Ogilvie et al., 2011 [27]
Kapp CYP2C19 (µM) 0.3 Optimized (c)
kinact CYP2C19 (1/h) 5.5 Optimized (c)
fumic 1 Simcyp default
Log P, octanol/water partition ratio; pKa, dissociation constant; B/P, blood/plasma partition ratio; fu, fraction
unbound; fa, fraction absorbed; ka, absorption rate constant; Qgut, gut flow; fugut, fraction unbound in enterocytes;
Vss, volume of distribution at steady state; CLR, renal clearance; fm, fraction metabolized; CLint, in vitro intrinsic
clearance; Ki, inhibitor concentration that supports half maximal inhibition; fumic, fraction unbound in vitro;
Kapp, inhibitor concentration that supports half the maximal rate of inactivation; kinact, maximal rate of enzyme
inactivation; fg, fraction escaping gut metabolism; (a) average value for CYP2C19 EM/RM/UM phenotypes [31];
(b) retrograde calculated value based on observed Clpo after 20 mg single dose of omeprazole (L/h) [30] assuming
fa * fg = 1 [28,43]; (c) optimized based on values for enantiomers [28].
The model was validated using clinical PK data from published trials in Caucasians
obtained after i.v. infusion of 30 mg gliclazide [35], single oral administration of the 80 mg
gliclazide IR tablet [44], and single oral administration of the 30 mg gliclazide MR tablet [35].
The simulations were performed using 10 virtual trials with 10 individuals in each trial,
matched for age, gender and body weight with respective clinical trial volunteers.
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Table 2. Input parameters for gliclazide PBPK model.
Parameter Value Method/Reference
Physicochemical properties
Molecular weight (g/mol) 323.4
Log P 2.04 El-Sabawi, et al., 2014 [45]
pKa 2.9; 5.8 Grbic et al., 2011 [40]
Compound type Ampholyte Grbic et al., 2011 [40]
B/P 0.68 Predicted by PK-Sim
fu 0.15 Proks et al., 2018 [46]
Absorption
Absorption model ADAM
Human jejunal effective permeability,
Peff,man (10−4 cm/s)
3.68 Grbic et al., 2011 [40]
Solubility pH-profile entered Grbic et al., 2011 [40]
Immediate Release Formulation Diffusion layer model fordissolution
Modified Release Formulation Experimental dissolutionprofile entered
Distribution
Distribution model Full PBPK model
Vss (L/kg) 0.306 Predicted by Simcyp (a)
Kp scalar 3.5 Estimated (b)
Elimination
fm CYP2C19 (%) 76 Tod et al., 2013 [36]
fm CYP2C9 (%) 24 Tod et al., 2013 [36]
Clint CYP2C19 (µL/min/pmol) 0.273 Calculated (c)
Clint CYP2C9 (µL/min/pmol) 0.004 Calculated (c)
fumic 0.82 Predicted by Simcyp
Transport
Intestinal MRP2 Clint,T (µL/min) 5.0 Optimized
Liver passive diffusion clearance
ClPD (mL/min/106 hepatocytes)
7.95 × 10−4 Calculated (d)
OATP1B1 Km (µM) 30.2 Chen et al., 2018 [37]
OATP1B1 Jmax (pmol/min/106 cells) 12.9 Chen et al., 2018 [37]
OATP1B1 RAF 5.75 Optimized
Log P, octanol/water partition ratio; pKa, dissociation constant; B/P, blood/plasma partition ratio; fu, fraction
unbound; Vss, volume of distribution at steady state; Kp scalar, scalar applied to all predicted tissue/plasma
partition coefficients; fm, fraction metabolized; CLint, in vitro intrinsic clearance; fumic, fraction unbound in the
in vitro microsomal incubations; Clint,T, in vitro transporter-mediated intrinsic clearance; ClPD, liver passive
diffusion clearance; Km, Michaelis–Menten constant; Jmax, maximum transport rate in vitro; RAF, relative activity
factor; (a) method by Rodgers et al. + ion membrane permeability; (b) estimated by matching the predicted Vss
value to the in vivo observed Vss values (0.19–0.46 L/kg); (c) calculated based on the microsomal total intrinsic
clearance [10], CYP abundances in the liver and the fm values [36]; (d) Calculated [38] based on logD7.4 value [39].
2.1.3. Simulation of Omeprazole-Gliclazide Interaction
We simulated the DDI study between omeprazole and gliclazide according to our
clinical trial protocol. The simulations were run for 192 h, using 10 virtual trials with
10 individuals in each virtual trial, matched for age, gender, body weight, and CYP2C9,
CYP2C19, and OATP1B1 phenotypes with the real trial volunteers. Virtual individuals
received 20 mg of oral omeprazole for 5 days, and an oral dose of 40 mg gliclazide was
co-administered on day 5.
In the next step, we performed simulations of DDI in virtual individuals who received
20 mg omeprazole for 5 days and 80 mg gliclazide IR tablet on day 5, for NM, RM/UM,
IM and PM phenotypes separately. Finally, we simulated real-world multiple dosing
scenarios with NM/RM/UM and IM individuals receiving daily 40 or 80 mg omeprazole
concomitantly with 80 mg gliclazide for 20 days.
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2.1.4. Assessment of PBPK Models Performance
The performance of the models was assessed by visual inspection of the plasma
concentration-time profiles and by comparison of the predicted PK parameters to the
clinically observed data (Cmax, tmax, AUC). Observed data from the literature were reported
as arithmetic means and standard deviations, geometric means with 95% confidence
intervals (CIs) or medians with range. For comparison with the simulated values, arithmetic
means were transformed to geometric means and 95% CIs, if these were not reported [47].
The fold error was calculated as the ratio of simulated and observed parameter values.
The predicted values within 2-fold range of observed data were considered acceptable.
For DDI evaluation, geometric mean ratios of predicted gliclazide Cmax and AUC0–∞
in the presence/absence of omeprazole were determined as follows:
DDI AUC ratio = AUC0–∞ of gliclazide co-administrated with omeprazole/AUC0–∞
of gliclazide administered alone (control).
DDI Cmax ratio = Cmax of gliclazide co-administrated with omeprazole/Cmax of gli-
clazide administered alone (control).




The study protocol was approved by the Ethics Committee of the General Hospital
“Prim. Dr. Abdulah Nakas” (100-78/18), and by the Ethics Committee of the Faculty
of Medicine, University of Sarajevo (02-3-4-8798/18), Sarajevo, Bosnia and Herzegovina
(B&H). All procedures were conducted in line with the Good Clinical Practice and the
Declaration of Helsinki. Prior to inclusion in the study, the nature and purpose of the
study were explained, in both written and verbal form, to each volunteer who then gave
the informed written consent to participate in the study. The study was registered at the
ClinicalTrials.gov (ID NCT04198948).
Fifteen healthy volunteers (men, age 18–30 years, non-smokers) with CYP2C19
NM/RM/UM status were recruited. The exclusion criteria included: a medical history
of hepatic, renal, gastrointestinal or hematologic disease or any acute or chronic disease;
drug allergy to sulfonylureas or PPIs; history of drug abuse; abnormalities in physical
examination, ECG or routine clinical laboratory tests (including fasting blood glucose
concentration); medication use during the 14 days prior to and during the study period;
grapefruit, grapefruit juice, alcohol, beverages or food containing methylxanthines use
during the 72 h prior to and during the study period.
2.2.2. Study Design
A randomized, placebo controlled, two-sequence, two-period crossover study, with
a 10-day washout between the study periods, was performed to compare the effects of
gliclazide (40 mg, half of an 80 mg tablet of Diprian®, Hemofarm d.o.o. Banja Luka,
B&H) combined with placebo with those of gliclazide combined with omeprazole (20 mg,
Ulcosan®, Bosnalijek d.d. Sarajevo, B&H). Prior to administration of gliclazide, omeprazole
or placebo was administered once daily at 8 AM for 4 days (on day 1 until day 4). On day
5 of each admission period, after an overnight fast, the volunteers were admitted to the
hospital. After the blood glucose level was measured using a glucometer, a single dose
of 40 mg gliclazide with 240 mL of water was co-administered with either omeprazole or
placebo, according to their treatment assignment. Drugs were given in a sitting position,
at 8 AM. Volunteers were not permitted to lie down or sleep for the next 4 h after taking
drugs, as well as to perform any strenuous activities for the next 24 h. In order to counteract
the blood glucose-lowering action of gliclazide, volunteers received standardized meals:
breakfast at 30 min after gliclazide intake, snacks after 2 and 3 h, a lunch (warm meal) after
4 h, a snack after 6 h, dinner after 8 h, and additional snacks at 10 h and 12 h after drugs
administration. No other food and drink (with the exception of water) were allowed. For
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safety reasons, the volunteers were under direct medical supervision throughout the 24 h
following drugs administration. Fast-acting carbohydrates, glucose solution for i.v. use
and glucagon for intramuscular use were available in case of hypoglycemia.
2.2.3. Sampling
Venous blood samples were collected on day 5 of each admission period before
dosing (0 h) and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 15 and 24 h after gliclazide
administration. Serum samples for gliclazide quantification were separated within 30 min
following each blood sample collection and stored at −80 ◦C until the analysis.
2.2.4. Quantification of Gliclazide
Serum gliclazide concentrations were quantified using a validated stable isotope
dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. In
brief, a total of 10 µL serum was added to 90 µL acetonitrile containing 100 ng/mL of d4-
gliclazide and 0.1% formic acid. After 5 s vortex and centrifugation at 16,110× g for 10 min
(4 ◦C), the supernatant was subjected to LC-MS/MS analysis using a Dionex U3000 LC
system connected to a Thermo Quantum Ultra mass spectrometer with an IonMax interface
(all instruments were from Thermo Scientific, Hemel Hempstead, United Kingdom). A
volume of 5 µL supernatant was injected by the LC system and the analytes were separated
on an Inertsil HILIC column (5 µm, 150 × 2.1 mm (Supelco)) using an isocratic mode at
a flow rate of 0.65 mL/min. Gliclazide was quantitated by the triple quadrupole mass
spectrometer in ESI positive ion mode. The targeted ion transitions (m/z) for gliclazide
and d4-gliclazide were 324–>127 and 328–>127, respectively. The ion spray voltage was
set at 4500 V, capillary temperature at 275 ◦C, acquisition time at 100 ms, the resolution of
both quadrupoles at 0.7, collision gas pressure (argon) at 1.5 mTorr, optimized collision
induced dissociation energy at 38 eV and tube lens voltage at 40 V. Calibration curves and
quality control samples were included in each batch of analysis. The intra- and inter-assay
imprecision (%CV) for gliclazide were 4 to 8% and 4 to 5%, respectively. The intra- and inter-
assay accuracy for gliclazide ranged from −13 to 1% and from −8 to −3%, respectively.
The limit of quantification was 3.1 ng/mL.
2.2.5. Pharmacokinetic Analysis
PK parameters were calculated in a noncompartmental analysis using PKSolver, a
program for PK data analysis in Microsoft Excel. The area under the plasma gliclazide
concentration-time curve (AUC) up to the last concentration measured (AUC0–t) was
determined using the linear trapezoidal rule.
2.2.6. Genotyping
Genomic DNA was extracted from blood samples by QIAamp DNA Blood Midi Kit
(Qiagen, Hilden, Germany). Polymorphisms in the CYP2C19 gene: CYP2C19*2 (rs4244285)
and CYP2C19*17 (rs12248560), CYP2C9 gene: CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910),
and c.521T>C (rs4149056) variant in the SLCO1B1 gene were genotyped by specific TaqMan
Drug Metabolism SNP genotyping assays (Applied Biosystems, Foster City, CA, USA).
The following CYP2C19 phenotypes were assigned based on diplotypes: NM (*1/*1),
RM (*1/*17), UM (*17/*17), IM (*1/*2, *2/*17) and PM (*2/*2) [25]. All volunteers were
non-carriers of the CYP2C19*2 allele and thus NM, RM or UM metabolizers. For CYP2C9
assigned phenotypes were: NM (*1/*1), IM (*1/*2, *1/*3, *2/*2) and PM (*2/*3, *3/*3) [24].
For OATP1B1 (SLCO1B1 gene), the following phenotypes were assigned based on the
rs4149056 genotype: normal transporter (c.521TT), intermediate transporter (c.521TC) and
poor transporter (c.521CC) phenotype [48].
2.2.7. Statistical Analysis
The main evaluated outcome was systemic exposure to gliclazide, expressed as AUC0–t.
The geometric mean was calculated for AUC0–24. The ratio of the geometric means with
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90% CIs was assessed by linear mixed models between the two treatment assignments:
gliclazide and omeprazole co-administration to that of gliclazide and placebo. The obtained
90% CI was compared with the equivalence 0.8–1.25 range. The statistical analyses were
performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
2.3. In Vitro Dissolution Testing
2.3.1. Materials
Dissolution studies were performed with two gliclazide tablets commercially available
on B&H market: half of the 80 mg Diprian® tablet (tablets with the same batch number as
those used in a current trial), and the 60 mg Diaprel® MR tablet (Les Laboratoires Servier
Industrie, Gidy, France). As the 30 mg Diamicron® MR tablets administered in a published
clinical study we simulated [35] were not available on B&H market, we used instead
gliclazide MR formulation, the 60 mg Diaprel® MR tablets, from the same manufacturer
(Servier) as an approximate substitute, assuming similar dissolution profile.
Gliclazide reference standard was used for quantification (British Pharmacopoeia
Chemical Reference Substance, 99.9% purity). Other used reagents were of p.a. grade.
Di-potassium hydrogen phosphate and potassium hydroxide were purchased from Merck
(Darmstadt, Germany), potassium dihydrogen phosphate from Fisher Chemical (Thermo
Fisher Scientific, Leicestershire, UK) and 37% hydrochloric acid from Carlo Erba (Mi-
lan, Italy).
2.3.2. Test Procedure
In order to estimate the drug release rate in vivo and concomitant absorption profile,
dissolution tests were performed under biorelevant media-change conditions (Table 3),
using USP apparatus 2 (Erweka DT 800, Heusenstamm, Germany) at 37 ± 0.5 ◦C and
rotational speed of 100 rpm. Withdrawn aliquots were filtered, diluted and analysed for
gliclazide by UV spectrophotometry (UV-1700 spectrophotometer, Shimadzu, Japan). The
absorbance obtained at 226 nm was corrected by subtracting the absorbance obtained
at 290 nm, according to British Pharmacopeia [49]. All measurements were performed
in triplicate.
Table 3. Dissolution test conditions.
Represented GI Region Stomach Duodenum andJejunum Ileum Colon
Conditions without omeprazole *
pH value/Volume
(mL)/Residence time (h) 1.6 (a)/300/0.5 5.8 (b)/900/2 6.8 (c)/900/1.5 6.0 (d)/900/22
Conditions with omeprazole *
pH value/Volume
(mL)/Residence time (h) 3.0 (e)/300/0.5 5.8 (f)/900/2 6.8 (c)/900/1.5 6.0 (d)/900/22
* Conditions simulating gastric pH effects of omeprazole use; GI, gastrointestinal; (a) 0.03 M HCl solution; (b) the pH adjusted by the
addition of phosphate buffer (225 mL 0.15 M KH2PO4, 75 mL 0.15 M K2HPO4 and 300 mL H2O); (c) for media pH 6.8, the pH adjusted by
replacing the withdrawn media aliquot with an equal volume of 21 mL 1 M KOH solution; (d) the pH adjusted by the addition of 6 mL 3 M
HCl; (e) 0.03 M HCl solution adjusted to pH 3.0 by adding KOH pellets; (f) pH adjusted by the addition of phosphate buffer (270 mL 0.3 M
KH2PO4, 30 mL 0.3 M K2HPO4 and 300 mL H2O).
The pH values and tablet residence time in each medium were selected based on
the proposed biorelevant dissolution test conditions [50–52]. As volunteers in the clin-
ical trial received a breakfast 30 min after drug administration, and subsequent meals
afterwards, we simulated fasted pH values for the stomach, and fed state pH values for
duodenum, jejunum, ileum and colon. Medium pH 1.6 was used to simulate fasting
stomach pH value, medium pH 3.0 for fasting stomach pH after 5-day treatment with
omeprazole, medium pH 5.8 for fed duodenal and jejunal pH value, and medium pH 6.8
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for ileal pH value. Medium pH 6.0 was used to simulate the fed state luminal conditions in
the ascending colon [50].
2.4. Population Observational Study of Patients with T2D
We used the Scottish Ambulance Service data and the Accident and Emergency
diagnosis records to identify severe cases of hypoglycemia in Tayside and Fife, Scot-
land. The characteristics and selection of patients who had experienced a hypoglycemic
event and their respective controls were described previously [53]. From 173 cases and
826 controls who were treated with gliclazide, 48 cases and 288 controls were in the Genet-
ics of Diabetes Audit and Research Tayside Study (GoDARTS) and had available genotype
data for the two most common CYP2C19 variants, *2 (rs4244285) and *17 (rs12248560).
Logistic regression was used to analyze the effect of the CYP2C19 variants and co-treatment
with PPIs on gliclazide-induced hypoglycemia. All analyses were adjusted for known
clinical predictors of hypoglycemia, including age, sex, age of T2D diagnosis, body mass
index, creatinine and HbA1c [53], as well as the overall number of medications used as a
proxy for comorbidities [54]. The CYP2C19 phenotypes were assigned based on diplotypes
in the same manner as in healthy volunteers. The analyses were performed using SAS 9.3
(SAS Institute Inc., Cary, NC, USA). Statistical significance was set at p < 0.05.
3. Results
3.1. PBPK Model for Omeprazole
The generated omeprazole model was used to simulate published mean plasma
PK profiles obtained after single and multiple oral doses of the drug [30]. The simu-
lated plasma concentration-time profiles after repeated dosing, once daily for 5 days with
20-mg and 40-mg omeprazole oral solutions, are presented in Figure 1a,b, respectively.
The simulated profiles were in good accordance with clinically observed data. The non-
linear PK of omeprazole was well captured by optimized mechanism-based inhibition
parameters. The lowest simulated percentage of active CYP2C19 levels after 5-day dosing
of 40 mg omeprazole was 11% (Supplementary Figure S1). The predicted Cmax and AUC
values were within 1.1-fold of the observed data (Table 4).
Table 4. Comparison of PK parameters between the simulated and observed data for omeprazole.
Dosing PK Parameter Observed Simulated Fold Error Simu-lated/Observed
20 mg day 1 Cmax (µM) 1.04 (0.75–1.44) 1.10 (0.98–1.23) 1.06
AUC0–∞ (µM × h) 1.04 (0.64–1.72) 0.97 (0.81–1.17) 0.93
20 mg day 5 Cmax (µM) 1.43 (1.02–2.00) 1.52 (1.35–1.72) 1.06
AUC0–∞ (µM × h) 1.63 (0.96–2.78) 1.67 (1.36–2.05) 1.02
40 mg day 1 Cmax (µM) 2.32 (1.71–3.16) 2.63 (2.34–2.95) 1.13
AUC0–∞ (µM × h) 2.44 (1.53–3.91) 2.79 (2.30–3.38) 1.14
40 mg day 5 Cmax (µM) 3.87 (2.99–5.02) 4.00 (3.58–4.48) 1.03
AUC0–∞ (µM × h) 5.79 (3.60–9.33) 5.57 (4.56–6.79) 0.96
Data are shown as geometric means with 95% CIs. Observed data are from Hassan-Alin et al., 2005 [30].
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3.2. PBPK Model for Gliclazide
As described above, a PBPK model for gliclazide was developed based on the combi-
nation of in vitro, in silico and in vivo input data (Table 2).
Simulations were performed to match the protocol and conditions from clinical trials
in Caucasians reported in the literature. The concentration-time profiles following 30 mg
gliclazide i.v. infusion [35], single oral administration of gliclazide 80 mg IR tablet [44], and
single oral administration of gliclazide 30 mg MR tablet [35], are shown in Figure 2.
The simulated PK profiles were in good agreement with published clinical data.
The predicted Cmax, tmax, and AUC values were within 0.80–1.38-fold of the observed data
(Table 5).
3.3. Interaction between Omeprazole and Gliclazide—Clinical Trial and Simulations
In our clinical trial, 14 out of 15 volunteers (men, mean age 22.6 ± 2.7 years, mean body
weight 79.8 ± 11.3 kg) completed both study periods. One volunteer was dropped from
the analysis as he only completed one study period. There were no cases of hypoglycemia
or any other adverse effect. The volunteers received half of the 80 mg Diprian® tablet
and were followed for only 24 h as the drug was registered as IR formulation in B&H.
However, the concentration-time profiles showed that gliclazide was not eliminated from
the body within 24 h and usual PK parameters including Cmax, tmax, t1/2, and AUC0–∞
could not be determined (Figure 3, observed data). As obtained PK profiles resembled
those seen with the MR formulations, we performed dissolution tests and confirmed
the MR dissolution profile of Diprian. The experimentally obtained dissolution profile
(Supplementary Figure S2a) was used as input data to simulate bioperformance of Diprian®
tablets. There was no difference in the initial gliclazide release rate between media pH 1.6
and pH 3.0. The mean cumulative amount of gliclazide dissolved after 26 h from Diaprel®
tablets was 89%, whereas only 37% of gliclazide was dissolved from Diprian® tablets
(Supplementary Figure S2).
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Table 5. Comparison of PK parameters between simulated and observed data for gliclazide.
Dosing (Study) PK Parameter Observed Simulated Fold ErrorSimulated/Observed
i.v. infusion 30 mg [35] Cmax (µg/mL) 1.39 (1.16–1.67) 1.54 (1.51–1.58) 1.11
AUC0–72 (µgh/mL) 15.5 (13.0–18.5) 21.4 (19.1–24.0) 1.38
AUC0–∞ (µgh/mL) 17.2 (14.5–20.3) 22.9 (19.9–26.2) 1.33
80 mg IR tablet [44] Cmax (µg/mL) 3.51 (3.24–3.80) 2.81 (2.70–2.91) 0.80
tmax (h) 3.66 (3.10–4.33) 3.54 (3.35–3.73) 0.97
AUC0–48 (µgh/mL) 45.5 (38.9–53.3) 51.0 (45.8–56.9) 1.12
AUC0–∞ (µgh/mL) 50.9 (42.8–60.5) 59.1 (51.1–68.4) 1.16
30 mg MR tablet [35] Cmax (µg/mL) 0.71 (0.62–0.82) 0.70 (0.66–0.74) 0.99
tmax (h) * 7 (4–10) 8.4 (5.1–13.5) 1.20
AUC0–72 (µgh/mL) 14.4 (12.4–16.8) 15.7 (13.9–17.8) 1.09
AUC0–∞ (µgh/mL) 15.6 (13.5–18.1) 17.0 (14.7–19.7) 1.09
40 mg tablet (current trial,
placebo phase) Cmax (µg/mL) - 0.18 (0.17–0.19) -
tmax (h) * - 15.4 (4.4–26.8) -
AUC0–24 (µgh/mL) 3.29 (2.65–4.09) 3.33 (3.09–3.59) 1.01
AUC0–96 (µgh/mL) - 5.51 (4.89–6.21) -
AUC0–∞ (µgh/mL) - 5.61 (4.96–6.36) -
40 mg tablet (current trial,
omeprazole phase) Cmax (µg/mL) - 0.23 (0.21–0.25) -
tmax (h) * - 17.7 (4.5–27.2) -
AUC0–24 (µgh/mL) 3.73 (2.81–4.93) 4.09 (3.78–4.42) 1.10
AUC0–96 (µgh/mL) - 7.65 (6.72–8.71) -
AUC0–∞ (µgh/mL) - 7.86 (6.86–9.00) -
Data are shown as geometric means with 95% confidence intervals (CIs), or as * medians (minimum–maximum).
Still, the observed PK profiles up to 24 h showed higher mean gliclazide AUC0–24 in
the omeprazole phase compared to the placebo phase. The geometric mean ratio and 90%
CI for gliclazide AUC0–24 between omeprazole and placebo phase was 1.13 (0.86–1.48),
with upper confidence limit above the usual 1.25 boundary.
The observed and simulated PK profiles following co-administration of 40 mg gli-
clazide (the half of 80 mg Diprian® tablet) with placebo or omeprazole are shown in
Figure 3. The simulated profiles of gliclazide in both placebo and omeprazole phase cap-
tured well the observed data collected up to 24 h, with the predicted AUC0–24 within 1.0
and 1.1-fold of the observed data, respectively (Table 5). The simulated DDI Cmax and AUC
ratios for the current trial, as well as different CYP2C19 phenotypes, are shown in Table 6.
Table 6. Simulated DDI Cmax and AUC ratios for interaction between omeprazole and gliclazide.
Population Gliclazide Dosing Cmax Ratio AUC Ratio
Current in vivo trial (NM/RM/UM) 40 mg Diprian® tablet 1.26 (1.23–1.29) 1.40 (1.35–1.45)
NM/RM/UM 40 mg IR tablet 1.09 (1.08–1.10) 1.50 (1.44–1.56)
NM 80 mg IR tablet 1.10 (1.09–1.11) 1.55 (1.49–1.60)
RM/UM 80 mg IR tablet 1.10 (1.09–1.11) 1.49 (1.43–1.55)
IM 80 mg IR tablet 1.06 (1.06–1.07) 1.40 (1.36–1.43)
PM 80 mg IR tablet 1.00 (1.00–1.00) 1.01 (1.01–1.01)
Omeprazole (20 mg) was administered for 5 days, and a single dose of gliclazide was administered on day 5. DDI Cmax and AUC0–∞
geometric mean ratios are shown with 90% CIs. NM, normal metabolizers; RM, rapid metabolizers; UM, ultrarapid metabolizers; IM,
intermediate metabolizers; PM, poor metabolizers.
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Figure 3. Observed (current trial, circles) and simulated (lines) plasma concentration-time profiles of gliclazide following
oral administration of 40 mg gliclazide (half of 80 mg Diprian® tablet) with placebo (black circles, solid line) or with 20 mg
omeprazole (grey circles, dashed line). Lines represent the mean values for the whole virtual population. The mean values
of the individual virtual trials were omitted for clarity.
The predicted DDI AUC ratio for the current in vivo study was 1.40. If gliclazide IR
tablets with comp ete abs rption had been ad inis ered, the AUC ratio would have been
1.50, according to the model. The highest AUC ratio was predicted for NM phenotype,
whereas for PM individu ls no interaction was observed.
In the next step, we simulated four clinical scenarios of concomitant treatment of 80 mg
gliclazide IR tablet once daily and 40 mg omeprazole once or twice daily in NM/RM/UM
and IM individuals for 20 days. The simulated DDI Cmax and AUC geometric mean ratios
(90% CIs) are shown in Table 7. The predicted AUC increased 2.1 and 2.5-fold in IM
individuals, and 2.6 3.8-fold in NM/RM/UM group, after 20 days of conco itant
gliclazide administration with 40 mg omeprazole once and twice daily, respectively. The
simulated concentration-time profiles of gliclazide during co-administration with 40 mg
omeprazole twice daily in NM/RM/UM individuals are shown in Figure 4.
Table 7. Simulated DDI Cmax and AUC ratios for interaction between omeprazole and gliclazide
after 20 days of concomitant dosing.
Population Omepr zole Dosing Cmax Ratio AUC Ratio
NM/RM/UM 40 mg q.d. 1.67 (1.60–1.75) 2.57 (2.39–2.76)
N R /UM 40 mg b.i.d. 2.11 (1.99–2.25) 3.80 (3.48–4.15)
IM 40 mg q.d. 1.60 (1.53–1.67) 2.13 (2.00–2.27)
IM 40 mg b.i.d. 1.78 (1.69–1.88) 2.53 (2.35–2.73)
Gliclazide (80 mg IR tablet) and omeprazole were administered concomitantly for 20 days. DDI Cmax and
AUC0–96 ratios on day 20 are shown as geometric mean ratios with 90% CIs. NM, normal metabolizers; RM, rapid
metabolizers; UM, ultrarapid metabolizers; IM, intermediate metabolizers; q.d., once daily; b.i.d., twice daily.
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The concomitant treatment with PPIs was not associated with increased odds of se-
vere hypoglycemia in the whole group of T2D patients treated with gliclazide (173 pa-
tients and 826 controls), odds ratio (OR) (95% CI): OR = 1.33 (0.88–2.00), p = 0.173. Similar 
results were obtained for omeprazole, which was the most commonly used PPI drug in 
the cohort [OR = 1.31 (0.85–2.03), p = 0.221]. The loss-of-function CYP2C19*2 allele was not 
associated with hypoglycemia in the cohort with available genetic data (48 cases and 288 
controls), OR = 0.50 (0.18–1.40), p = 0.187.  
However, when stratified by the CYP2C19 phenotypes, the co-treatment with PPIs 
was associated with severe hypoglycemia only in CYP2C19*2 non-carriers [OR = 2.34 
(1.02–5.37), p = 0.044] (Figure 5). This effect was mostly driven by omeprazole, which in-
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Figure 4. Simulated plasma concentration-time profiles of gliclazide following oral administration of 80 mg gliclazide IR
tablet once daily alone (solid line) or concomitantly with 40 mg omeprazole twice daily (dashed line) in NM/RM/UM
individuals for 20 days. Lines represent the mean values for the whole virtual population. The mean values of the individual
virtual trials were omitted for clarity.
3.4. Omeprazole Treatment and the Risk of Severe Gliclazide-Induced Hypoglycemia in Patients
with T2D
The concomitant treatment with PPIs was not associated with increased odds of severe
hypoglycemia in the whole group of T2D patients treated with gliclazide (173 patients and
826 controls), odds ratio (OR) (95% CI): OR = 1.33 (0.88–2.00), p = 0.173. Similar results
were obtained for omeprazole, which was the most commonly used PPI drug in the cohort
[OR = 1.31 (0.85–2.03), p = 0.221]. The loss-of-function CYP2C19*2 allele was not associated
with hypoglycemia in the cohort with available genetic data (48 cases and 288 controls),
OR = 0.50 (0.18–1.40), p = 0.187.
However, when stratified by the CYP2C19 phenotypes, the co-treatment with PPIs
was associated with severe hypoglycemia only in CYP2C19*2 non-carriers [OR = 2.34
(1.02–5.37), p = 0.044] (Figure 5). This effect was mostly driven by omeprazole, which
increased the odds of severe hypoglycemia over three-fold in patients with CYP2C19
NM/RM/UM phenotype treated with gliclazide [OR = 3.26 (1.44–7.38), p = 0.005]
(Figure 5).
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nism-based inhibition of CYP2C19 by omeprazole (Kapp and kinact) using published data 
OR = 2.34 (1.02– 5.37)
P = 0.044, N=42/225
OR = 3.26 (1.44– 7.38)

















All PPIs                                                                          Omeprazole
CYP2C19 *1/*1, *1/*17, *17/*17 carriers
Figure 5. Effect of co-treatment with PPIs and omeprazole on gliclazide-induced hypoglycemia in T2D patients with
CYP2C19 NM/RM/UM phenotype. Data are shown as odds ratios (OR) with 95% CIs. N, number of cases with hypo-
glycemia and controls.
4. Discussion
This is the first study that explored the possible interaction between omeprazole
and gliclazide. We used PBPK modeling approach to predict the effects of omeprazole
on gliclazide PK and validated developed models using data from the clinical trial in
healthy volunteers. In addition, we explored the influence of omeprazole on risk of
severe hypoglycemia in real-world patients with T2D treated with gliclazide. Our results
collectively suggest that omeprazole can increase exposure to gliclazide and thus increase
the risk of side effects in individuals treated concomitantly with these two drugs if CYP2C19
enzyme is functional.
We first developed a PBPK model for omeprazole. Although Simcyp has a built-in
model for omeprazole and few PBPK models for omeprazole were published
earlier [27–29,42], the models did not perform well in the current version of Simcyp.
Among others, one of the reasons is different and updated liver abundances of the en-
zymes. Considering that we were exploring interaction via polymorphic CYP2C19, we
updated the phenotype frequencies of CYP2C9 and CYP2C19 enzymes and changed their
abundancies in the liver according to the estimated enzyme activity scores for each pheno-
type. As the intrinsic clearance (Clint) values for enzymes depend on their abundancies,
they were back calculated based on in vivo clearance data. Although it is better to use
in vivo clearance from i.v. administration in the retrograde model for Clint calculations, we
used oral clearance value as it was reported for subjects with known CYP2C19 phenotype
(NM/RM/UM phenotype), and gut metabolism of omeprazole is expected to be negli-
gible [43]. The non-linear PK of omeprazole was previously best captured by published
odels for omeprazole enantio ers [28]. We managed to optimise values for parameters
related to mechanism-based inhibition of CYP2C19 by omeprazole (Kapp and kinact) us-
ing published data for enantiomers as starting values [28]. The simulation of changes in
the amount of active CYP2C19 following 5-day dosing with 40 mg omeprazole once
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daily showed that the lowest level of active CYP2C19 was 11% of baseline, in line with
the predicted lowest level of 14% obtained in a previous study based on enantiomers [28].
The model simulated well four drug plasma concentration-time profiles, as well as Cmax
and AUC values following single and multiple oral administration of 20 mg and 40 mg
omeprazole. All predicted PK parameters were within 1.1-fold of the clinical data.
The model for gliclazide was developed using in vitro, in silico and in vivo data as
inputs. As gliclazide is a substrate of liver OATP1B1 transporter [37], which can con-
tribute to its liver uptake and hence the metabolism and elimination, the Clint values for
enzyme kinetics could not be back calculated from the in vivo data. Only one in vitro
study of gliclazide metabolism was published using human liver microsomes and a panel
of recombinant human CYPs [10]. Based on the total microsomal intrinsic clearance,
and the percentage of inhibition of metabolic pathways by CYP selective inhibitors, the
contribution of CYP2C9 to gliclazide metabolism was estimated to be at least 65%, and
CYP2C19 maximally 35% according to this study [10]. However, microsomes were pre-
pared from six human livers which were not genotyped for CYP2C19 polymorphisms.
Furthermore, later in vivo studies showed that gliclazide PK is affected mainly by CYP2C19
polymorphisms [11,12,55]. Based on these PK clinical studies in individuals with different
CYP2C19 and CYP2C9 genotypes [11,12], it was estimated that the contribution of CYP2C9
to gliclazide metabolism is around 24%, and of CYP2C19 around 76% [36]. Taking this
into account, the Clint values for enzymes were calculated based on the overall in vitro
microsomal intrinsic clearance [10], and fm values estimated from in vivo studies [36].
By using enzyme Clint values only, clearance of the drug after i.v. administration was
largely underpredicted. Therefore, we extended our model to include in vitro obtained
values for OATP1B1-mediated gliclazide transport [37], and optimized RAF value for
the transporter to fit the observed data after i.v. drug administration [35], as well as
after oral drug dosing [35,44]. Namely, only one study describing gliclazide PK after i.v.
administration was found in the literature and referred to i.v. infusion [35], so oral drug
dosing studies were also taken into account. The RAF or relative expression factor (REF)
frequently needs to be optimized in the PBPK models due to a difference in expression of
the transporter between liver and the transfected cell line. The RAF value of 5.75 was in line
with bottom-up derived REF values of 5.9 and 8.7 for different OATP1B1 substrates [56]
based on measured OATP1B1 expression in the liver [57], isolated hepatocytes [57], and
transfected HEK-293 cells in other studies [56].
Another parameter that had to be optimized was MRP2-mediated intrinsic clearance
as tmax values for oral formulations were underpredicted in the preliminary simulations.
It has been shown that gliclazide is a substrate for gut Mrp2 and Mrp3 transporters in
rats [41], but in vitro and human data are lacking. As intestinal basolateral transporters are
not yet included in the Simcyp ADAM model, only apical transporter MRP2 was added
to the model. After this adjustment, the simulated tmax values were in accordance with
the observed data after oral drug dosing.
The simulations of gliclazide PK showed good agreement with clinical data after i.v.
infusion, and oral administration of gliclazide IR and MR tablets. The model showed that
only 30% (19–43%) of gliclazide was absorbed in our current clinical trial. The simula-
tion of the interaction showed that the predicted DDI AUC ratio of gliclazide between
omeprazole and placebo phases was 1.40 (1.35–1.45). The predicted ratio would have been
1.50 (1.44–1.56) if IR tablets with complete absorption were administered. The predicted
DDI Cmax ratio for the current trial was 1.26 (1.23–1.29), however, Cmax would not have
been impacted significantly by omeprazole dosing if gliclazide IR tablets were administered,
according to the model.
The simulated DDI AUC ratio after 5-day dosing with 20 mg omeprazole was 1.55, 1.49,
1.40, and 1.01 for NM, RM/UM, IM and PM individuals, respectively. A slightly lower AUC
ratio in RM/UM compared with NM individuals was due to lower predicted omeprazole
systemic and liver concentrations and thus weaker inhibitory effect on CYP2C19. The
lowest simulated percentage of active CYP2C19 was 31% in RM/UM compared to 21% in
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NM individuals. On the other hand, AUC ratio of 1.40 in IM individuals was comparable
to the ratios obtained in NM and RM/UM phenotypes. Although simulated CYP2C19 fm
value for gliclazide in IM individuals was only 59%, the interaction effect was similar to
the one in the NM/RM/UM group, due to higher predicted systemic concentrations of
omeprazole. As expected, no interaction effect in PM subjects was found due to low or
absent CYP2C19.
Although the predicted omeprazole-gliclazide interaction effect was not large, when
we simulated clinical scenarios of concomitant multiple dosing of both drugs for
20 days in NM/RM/UM individuals, the DDI AUC ratio increased to 2.57 (2.39–2.76)
if 40 mg omeprazole was administered once daily, and to 3.80 (3.48–4.15) if it was ad-
ministered twice daily. The predicted DDI AUC ratio in IM individuals also increased to
2.13 (2.00–2.27) and 2.53 (2.35–2.73) after co-administration of 40 mg omeprazole once and
twice daily, respectively.
We used the Simcyp population of healthy volunteers for all simulations, as there is
no special built-in population of patients with T2D in the Simcyp. However, considering
the older age of these patients and possible age-related PK changes such as limited drug
clearance due to decreased liver blood flow and reduced kidney function, as well as
frequent concomitant therapy with other interacting drugs, the concentrations of drugs
and thus interaction effect can be greater in older patients compared to young healthy
volunteers [58]. Interestingly, a recent study found lower mean metabolic activities of
CYP2C19, CYP2B6, and CYP3A enzymes in patients with T2D compared to non-T2D
individuals [59]. However, although lower activity of CYP2C19 can decrease the CYP2C19
fm value for gliclazide, the inhibition of CYP21C9 could be stronger due to higher systemic
concentrations of omeprazole. In line with this, in a study that explored the effect of
ageing on omeprazole PK, the omeprazole AUC was higher in elderly compared to young
Japanese volunteers following single i.v. dose of omeprazole [60].
Finally, we explored the effect of co-treatment with omeprazole and other PPI drugs
in real-world patients with T2D treated with gliclazide. Although patient cohort with
available genetic data was not large, we showed that patients with CYP2C19 NM/RM/UM
phenotype treated with omeprazole had 3.26-fold (1.44–7.38) higher odds of severe hypo-
glycemia. These results corroborate higher systemic exposure to gliclazide predicted for
NM/RM/UM individuals. No effect was seen in a very small group of patients carrying
CYP2C19*2 allele.
To our best knowledge, there have been no studies exploring potential interaction
between any PPI and gliclazide. Data regarding potential DDI between PPIs and other SUs
in humans are also limited. One study conducted in healthy volunteers showed no effect of
pantoprazole on glibenclamide PK [61]. As glibenclamide is metabolized by CYP2C9 and
CYP3A4, and other SUs, including glimepiride, glipizide and gliquidone, are metabolized
mostly by CYP2C9 [62], potential PK interactions with PPIs are not expected. On the other
hand, other PPIs could also interact with gliclazide via CYP2C19, however, except for
esomeprazole, their potential for DDIs seems to be weaker [15].
The main limitation of our study are incomplete in vivo gliclazide PK profiles in
omeprazole and placebo phase obtained in the current clinical trial. After we informed
the Agency for Medicines and Medical Devices of Bosnia and Herzegovina about the
unexpected MR profile of Diprian® tablets, the drug was withdrawn from the market and
thus patients in B&H stopped receiving this possibly inefficient drug. Still, we had collected
data up to 24 h, when drug elimination had mostly prevailed, and PK profiles in both
phases were well simulated. Our PBPK models confirmed the mechanistic hypothesis of
the interaction between the two drugs via polymorphic CYP2C19 enzyme and also allowed
us to predict different clinical scenarios.
Our results have potential clinical relevance. The predicted increase in gliclazide AUC
after 20-day of concomitant dosing with omeprazole shows that NM/RM/UM individuals
may have almost 4-times higher exposure to gliclazide. This is in line with over 3-fold
higher odds of hypoglycemia seen in NM/RM/UM patients with T2D treated concomi-
J. Pers. Med. 2021, 11, 367 18 of 21
tantly with omeprazole and gliclazide. The predicted AUC increase in IM individuals was
lower but still over 2-fold. This may lead to an increased risk of gliclazide side effects in all
patients treated with omeprazole, except those with the CYP2C19 PM phenotype. The risk
may be even higher if other clinical risk factors for hypoglycemia are present. Avoiding
co-prescribing omeprazole in these patients may prevent serious consequences of severe
hypoglycemia induced by gliclazide treatment.
In conclusion, we applied PBPK models to simulate the clinical PK profiles and to
assess the potential interaction between omeprazole and gliclazide. Developed models
predicted 1.4–1.6-fold higher gliclazide AUC in all CYP2C19 phenotypes except PM, after
5-day treatment with 20 mg omeprazole. The predicted gliclazide AUC increased 2.1 and
2.5-fold in IM individuals, and 2.6 and 3.8-fold in the NM/RM/UM group after 20 days
of concomitant gliclazide administration with 40 mg omeprazole once and twice daily,
respectively. The predicted results were corroborated by findings in patients with T2D
which demonstrated over 3-fold higher odds of severe gliclazide-induced hypoglycemia in
patients with CYP2C19 NM/RM/UM phenotype treated with omeprazole. These results
indicate that omeprazole may increase the risk of hypoglycemia in the majority of patients
treated with gliclazide. Further studies are needed to confirm this previously unrecognized
but potentially serious DDI and drug–drug–gene interaction.
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.3390/jpm11050367/s1, Figure S1: Simulation of the amount of active CYP2C19 during 5-day dosing
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Diprian® tablets (a) and 60 mg Diaprel® MR tablets (b).
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